74 related articles for article (PubMed ID: 15067105)
1. Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.
Morita S; Toi M; Kobayashi T; Ito Y; Hozumi Y; Ohno S; Iwata H; Sakamoto J
Jpn J Clin Oncol; 2004 Feb; 34(2):104-6. PubMed ID: 15067105
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.
Saji S; Toi M; Morita S; Iwata H; Ito Y; Ohno S; Kobayashi T; Hozumi Y; Sakamoto J
Oncology; 2007; 72(5-6):330-7. PubMed ID: 18187954
[TBL] [Abstract][Full Text] [Related]
3. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Mauriac L; Cufer T; Schaefer P; Atalay G; Piccart M
Eur J Cancer; 2003 Jun; 39(9):1277-83. PubMed ID: 12763217
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
5. [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Horiguchi J; Koibuchi Y; Rokutanda N; Nagaoka R; Kikuchi M; Sato A; Odawara H; Ishikawa Y; Tokiniwa H; Iino Y; Takeyoshi I
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1877-81. PubMed ID: 19011335
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Asola R; Kokko R; Ahlgren J; Auvinen P; Hemminki A; Paija O; Helle L; Nuortio L; Villman K; Nilsson G; Lahtela SL; Lehtiö K; Pajunen M; Poikonen P; Nyandoto P; Kataja V; Bono P; Leinonen M; Lindman H;
Lancet Oncol; 2009 Dec; 10(12):1145-51. PubMed ID: 19906561
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
8. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
9. [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Sano M; Tokuda Y; Noguchi S; Aogi K; Saeki T; Tabei T; Hatake K; Fujii H
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1091-7. PubMed ID: 16912527
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Becerra CR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):46-8. PubMed ID: 15685835
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
13. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Kelly CM; Green MC; Broglio K; Thomas ES; Brewster AM; Valero V; Ibrahim NK; Gonzalez-Angulo AM; Booser DJ; Walters RS; Hunt KK; Hortobagyi GN; Buzdar AU
J Clin Oncol; 2012 Mar; 30(9):930-5. PubMed ID: 22331946
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Dupont J; Jensen HA; Jensen BV; Pfeiffer P
Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
[TBL] [Abstract][Full Text] [Related]
17. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
19. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
20. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Hatschek T; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Lindh B; Loman N; Malmberg M; Rotstein S; Söderberg M; Sundquist M; Walz TM; Hellström M; Svensson H; Aström G; Brandberg Y; Carstensen J; Fernö M; Bergh J
Breast Cancer Res Treat; 2012 Feb; 131(3):939-47. PubMed ID: 22094937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
